Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D

Yu Tanaka, Mirai Tsukuda, Gaku Yamamoto, Eri Sugiyama, Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Yoshitaka Zenke, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Hibiki Udagawa

Cancer Res (2025) 85 (8_Supplement_1): 7198.

https://doi.org/10.1158/1538-7445.AM2025-7198

Published: 21 April 2025

View articletitled, Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D

Journal Articles

Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Gaku Yamamoto, Yu Tanaka, Yoshitaka Zenke, Jie Liu, Tetsuya Sakai, Hiroki Izumi, Eri Sugiyama, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Susumu S. Kobayashi, Hibiki Udagawa

Cancer Res (2025) 85 (8_Supplement_1): 4714.

https://doi.org/10.1158/1538-7445.AM2025-4714

Published: 21 April 2025

View articletitled, Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Journal Articles

Abstract CT280: FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)

Cancer Res (2024) 84 (7_Supplement): CT280.

https://doi.org/10.1158/1538-7445.AM2024-CT280

Published: 05 April 2024

View articletitled, Abstract CT280: FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)

Journal Articles

Abstract 6686: The mechanism of gut microbiome-mediated immune activation on the clinical efficacy of PD-1 blocking treatment in solid tumors

Cancer Res (2024) 84 (6_Supplement): 6686.

https://doi.org/10.1158/1538-7445.AM2024-6686

Published: 22 March 2024

View articletitled, Abstract 6686: The mechanism of gut microbiome-mediated immune activation on the clinical efficacy of PD-1 blocking treatment in solid tumors

Journal Articles

Abstract 1958: EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs

Tomohiro Takehara, Monique B. Nilsson, Ximeng Liu, Hibiki Udagawa, Naoto Morikawa, Alissa Poteete, Junqin He, Xiaoxing Yu, Thiru Arumugam, Koichi Goto, John V. Heymach

Cancer Res (2024) 84 (6_Supplement): 1958.

https://doi.org/10.1158/1538-7445.AM2024-1958

Published: 22 March 2024

View articletitled, Abstract 1958: EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs

Journal Articles

Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation

Cancer Res (2023) 83 (8_Supplement): CT126.

https://doi.org/10.1158/1538-7445.AM2023-CT126

Published: 14 April 2023

View articletitled, Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation

Journal Articles

Abstract 1026: A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer

Tetsuya Sakai, Yoshitaka Zenke, Mami Onishi, Eri Morita, Masatoshi Yanagida, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Cancer Res (2023) 83 (7_Supplement): 1026.

https://doi.org/10.1158/1538-7445.AM2023-1026

Published: 04 April 2023

View articletitled, Abstract 1026: A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer

Journal Articles

Abstract 3321: Development of a CTC-based novel diagnostic technology for unresectable non-small cell lung cancer

Mami Onishi, Eri Morita, Tetsuya Sakai, Yoshitaka Zenke, Masatoshi Yanagida, Koichi Goto

Cancer Res (2023) 83 (7_Supplement): 3321.

https://doi.org/10.1158/1538-7445.AM2023-3321

Published: 04 April 2023

View articletitled, Abstract 3321: Development of a CTC-based novel diagnostic technology for unresectable non-small cell lung cancer

Journal Articles

Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

Cancer Res (2023) 83 (7_Supplement): 2166.

https://doi.org/10.1158/1538-7445.AM2023-2166

Published: 04 April 2023

View articletitled, Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

Journal Articles

Abstract 5238: CLIP1-LTK: A novel druggable gene fusion in non-small cell lung cancer

Hiroki Izumi, Shingo Matsumoto, Jie Liu, Kosuke Tanaka, Shunta Mori, Shogo Kumagai, Takuma Hayashida, Yuji Shibata, Saori Takata, Eriko Tabata, Haruyasu Murakami, Reiko Taki, Satoshi Hara, Tomohiro Sakamoto, Koichi Goto, Susumu S. Kobayashi

Cancer Res (2022) 82 (12_Supplement): 5238.

https://doi.org/10.1158/1538-7445.AM2022-5238

Published: 15 June 2022

View articletitled, Abstract 5238: CLIP1-LTK: A novel druggable gene fusion in non-small cell lung cancer

Journal Articles

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

Cancer Res (2022) 82 (12_Supplement): CT034.

https://doi.org/10.1158/1538-7445.AM2022-CT034

Published: 15 June 2022

View articletitled, Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

Journal Articles

Abstract 5351: LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Shunta Mori, Hiroki Izumi, Jie Liu, Kosuke Tanaka, Shogo Kumagai, Takuma Hayashida, Yosuke Kagawa, Yuji Shibata, Shingo Matumoto, Koichi Goto, Susumu Kobayashi

Cancer Res (2022) 82 (12_Supplement): 5351.

https://doi.org/10.1158/1538-7445.AM2022-5351

Published: 15 June 2022

View articletitled, Abstract 5351: LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Journal Articles

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

Elaine Shum, Yasir Elamin, Karen L. Reckamp, Zofia Piotrowska, Julia Rotow, Daniel S. Tan, Koichi Goto, Jagan Parepally, Faris Albayya, Melinda Louie-Gao, Renata Sawtell, Alena Zalutskaya, David Spigel

Cancer Res (2022) 82 (12_Supplement): CT184.

https://doi.org/10.1158/1538-7445.AM2022-CT184

Published: 15 June 2022

View articletitled, Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

Journal Articles

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Yukie Kashima, Daisuke Shibahara, Ayako Suzuki, Kyoko Muto, Ikei S. Kobayashi, David Plotnick, Hibiki Udagawa, Hiroki Izumi, Yuji Shibata, Kosuke Tanaka, Masanori Fujii, Akihiro Ohashi, Masahide Seki, Koichi Goto, Katsuya Tsuchihara, Yutaka Suzuki, Susumu S. Kobayashi

Cancer Res (2021) 81 (18): 4835–4848.

https://doi.org/10.1158/0008-5472.CAN-20-2811

Published: 15 September 2021

View articletitled, Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Includes: Supplementary data

Journal Articles

Abstract CT106: Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20

Eiki Ichihara, Hiroyuki Yasuda, Yuta Takashima, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katsuyuki Kiura, Hideki Terai, Shinnosuke Ikemura, Koichi Goto, Kenzo Soejima

Cancer Res (2021) 81 (13_Supplement): CT106.

https://doi.org/10.1158/1538-7445.AM2021-CT106

Published: 01 July 2021

View articletitled, Abstract CT106: Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20

Journal Articles

Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR)

Masahiro Tsuboi, Kazuto Nishio, Kazuko Sakai, Hirotsugu Kenmotsu, Takeharu Yamanaka, Toshiaki Takahashi, Koichi Goto, Haruko Daga, Norihiko Ikeda, Takashi Seto, Shinichi Toyooka, Hiroshi Date, Tetsuya Mitsudomi, Isamu Okamoto, Hideo Saka, Hiroaki Okamoto, Yuichi Takiguchi, Nobuyuki Yamamoto

Cancer Res (2020) 80 (16_Supplement): 2052.

https://doi.org/10.1158/1538-7445.AM2020-2052

Published: 15 August 2020

View articletitled, Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR)

Journal Articles

Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC

Jun Sato, Tomoyuki Naito, Hibiki Udagawa, Hidehito Horinouchi, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe, Yoshitaka Zenke, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi, Genichiro Ishii, Koichi Goto

Cancer Res (2019) 79 (13_Supplement): 4919.

https://doi.org/10.1158/1538-7445.AM2019-4919

Published: 01 July 2019

View articletitled, Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC

Journal Articles

Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation

Tetsuya Sakai, Hibiki Udagawa, Yoshitaka Zenke, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Genichiro Ishii, Koichi Goto

Cancer Res (2019) 79 (13_Supplement): 4920.

https://doi.org/10.1158/1538-7445.AM2019-4920

Published: 01 July 2019

View articletitled, Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation

Journal Articles

Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor

Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Naomi Abe, Tomonori Haruma, Toshiharu Komori, Miki Terasaka, Ryoto Fujita, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, Daniel B. Costa, Susumu S. Kobayashi

Cancer Res (2019) 79 (13_Supplement): 1329.

https://doi.org/10.1158/1538-7445.AM2019-1329

Published: 01 July 2019

View articletitled, Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor

Journal Articles

Abstract 918: A secondary RET mutation allosterically conferring resistance to vandetanib

Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Nino, Rakhee Chauhan, Phillip P. Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki, Genichiro Ishii, Hitoshi Ichikawa, Yasushi Okuno, Kiyotaka Yoh, Neil Q. McDonald, Koichi Goto

Cancer Res (2018) 78 (13_Supplement): 918.

https://doi.org/10.1158/1538-7445.AM2018-918

Published: 01 July 2018

View articletitled, Abstract 918: A secondary RET mutation allosterically conferring resistance to vandetanib

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D

Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Abstract CT280: FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)

Abstract 6686: The mechanism of gut microbiome-mediated immune activation on the clinical efficacy of PD-1 blocking treatment in solid tumors

Abstract 1958: EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs

Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation

Abstract 1026: A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer

Abstract 3321: Development of a CTC-based novel diagnostic technology for unresectable non-small cell lung cancer

Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

Abstract 5238: CLIP1-LTK: A novel druggable gene fusion in non-small cell lung cancer

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

Abstract 5351: LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Abstract CT106: Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20

Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR)

Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC

Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation

Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor

Abstract 918: A secondary RET mutation allosterically conferring resistance to vandetanib

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only